Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023
13 Outubro 2023 - 5:10PM
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage
biopharmaceutical company focused on developing medicines to target
hypertension, chronic kidney disease (CKD) and other diseases
driven by abnormally elevated aldosterone, today announced upcoming
poster presentations at two scientific conferences being held in
November 2023, including:
ASN’s Kidney Week 2023 – Late-Breaking Poster
Details:
David Rodman, Chief Medical Officer of Mineralys, will present a
late-breaking poster highlighting lorundrostat’s treatment effect
in an endotype of hypertension at the American Society of
Nephrology’s (ASN) Kidney Week 2023, which is taking place November
2 - 5, 2023, in Philadelphia, PA. Poster details are below:
Poster Title: |
Identification
of a hypertensive endotype with a median treatment effect of
-32mmHg in response to the novel aldosterone synthase inhibitor
lorundrostat |
Presenter: |
Dr. David Rodman, Chief Medical Officer of Mineralys |
Poster Number: |
TH-PO1121 |
Session Title: |
Late-Breaking Posters |
Session Date/Time: |
Thursday, November 2nd from 10:00 a.m. to 12:00 p.m.
ET |
Session Location: |
Pennsylvania Convention Center, Exhibit Hall |
AHA Scientific Sessions 2023 – Poster
Details:
David Rodman, Chief Medical Officer of Mineralys, will present a
poster showing lorundrostat as a potential treatment for
obesity-related, aldosterone-dependent hypertension at the American
Heart Association (AHA) Scientific Sessions 2023, which is being
held from November 10 – 13, 2023, in Philadelphia, PA. Poster
details are below:
Poster Title: |
Lorundrostat
for Treatment of Obesity-Related, Aldosterone-Dependent
Hypertension - An Endotype-Specific, Targeted Approach to the
Treatment of Uncontrolled Hypertension |
Presenter: |
Dr. David Rodman, Chief Medical Officer of Mineralys |
Poster Number: |
4121 |
Session Title: |
Outcomes and Mechanisms of Treatment Approaches for
Hypertension |
Session Date/Time: |
Saturday, November 11th at 11:30 a.m. – 12:45 p.m. ET |
Session Location: |
Pennsylvania Convention Center, Zone 4, Science and Technology
Hall, Level 2 |
About HypertensionHaving sustained, elevated
blood pressure (or hypertension) increases the risk of heart
disease, heart attack and stroke, which are leading causes of death
in the U.S. In 2020, more than 670,000 deaths in the U.S. included
hypertension as a primary or contributing cause. Hypertension and
related health issues resulted in an average annual economic burden
of about $130 billion each year in the U.S., averaged over 12 years
from 2003 to 2014.
Less than 50 percent of hypertension patients achieve their
blood pressure goal with currently available medications.
Abnormally elevated aldosterone levels are a key factor in driving
hypertension in approximately 25 percent of all hypertensive
patients.
About LorundrostatLorundrostat is a
proprietary, orally administered, highly selective aldosterone
synthase inhibitor being developed for the treatment of
uncontrolled hypertension and CKD. Lorundrostat was designed to
reduce aldosterone levels by inhibiting CYP11B2, the enzyme
responsible for its production. Lorundrostat has 374-fold
selectivity for aldosterone-synthase inhibition versus
cortisol-synthase inhibition in vitro, an observed half-life of
10-12 hours and demonstrated approximately a 70% reduction in
plasma aldosterone concentration in hypertensive subjects.
About Mineralys TherapeuticsMineralys
Therapeutics is a clinical-stage biopharmaceutical company focused
on developing medicines to target hypertension, chronic kidney
disease and other diseases driven by abnormally elevated
aldosterone. Its initial product candidate, lorundrostat, is a
proprietary, orally administered, highly selective aldosterone
synthase inhibitor that Mineralys Therapeutics is developing for
cardiorenal conditions affected by abnormally elevated aldosterone,
including hypertension and CKD. Mineralys is based in Radnor,
Pennsylvania, and was founded by Catalys Pacific. For more
information, please visit https://mineralystx.com. Follow Mineralys
on LinkedIn and Twitter.
Forward-Looking StatementsMineralys
Therapeutics cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. The forward-looking statements are
based on our current beliefs and expectations and include, but are
not limited to, statements regarding: the potential therapeutic
benefits of lorundrostat; the Company’s expectation that
aldosterone synthase inhibitors with an SGLT2 inhibitor may provide
additive clinical benefits to patients; the Company’s expectation
that the Advance-HTN and the planned Phase 3 clinical trial of
lorundrostat may serve as pivotal trials in any submission of a new
drug application (NDA) to the United States Food and Drug
Administration (FDA); the Company’s ability to evaluate
lorundrostat as a potential treatment for CKD or obesity-related,
aldosterone-dependent hypertension; the planned future clinical
development of lorundrostat and the timing thereof; and the
expected timing of commencement and enrollment of patients in
clinical trials and topline results from clinical trials. Actual
results may differ from those set forth in this press release due
to the risks and uncertainties inherent in our business, including,
without limitation: our future performance is dependent entirely on
the success of lorundrostat; potential delays in the commencement,
enrollment and completion of clinical trials and nonclinical
studies; later developments with the FDA may be inconsistent with
the feedback from the completed end of Phase 2 meeting, including
whether the proposed pivotal program will support registration of
lorundrostat which is a review issue with the FDA upon submission
of an NDA; our dependence on third parties in connection with
manufacturing, research and clinical and nonclinical testing;
unexpected adverse side effects or inadequate efficacy of
lorundrostat that may limit its development, regulatory approval
and/or commercialization; unfavorable results from clinical trials
and nonclinical studies; results of prior clinical trials and
studies of lorundrostat are not necessarily predictive of future
results; our ability to maintain undisrupted business operations
due to any pandemic or future public health concerns; regulatory
developments in the United States and foreign countries; our
reliance on our exclusive license with Mitsubishi Tanabe Pharma to
provide us with intellectual property rights to develop and
commercialize lorundrostat; and other risks described in our
filings with the Securities and Exchange Commission (SEC),
including under the heading “Risk Factors” in our annual report on
Form 10-K, and any subsequent filings with the SEC. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and we
undertake no obligation to update such statements to reflect events
that occur or circumstances that exist after the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement, which is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995.
Contact:Investor
Relationsinvestorrelations@mineralystx.com
Media RelationsTom WeibleElixir
Health Public RelationsPhone: (1)
515-707-9678Email: tweible@elixirhealthpr.com
Mineralys Therapeutics (NASDAQ:MLYS)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Mineralys Therapeutics (NASDAQ:MLYS)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024